BDBM523918 US11136329, Compound 18::ethyl 2-(4-((7-(2- cyclohexylethyl)-7H- pyrrolo[2,3-d]pyrimidin-2- yl)amino)-1H-pyrazol-1- yl)acetate

SMILES CCOC(=O)Cn1cc(Nc2ncc3ccn(CCC4CCCCC4)c3n2)cn1

InChI Key InChIKey=FNTMZDFGABIUOJ-UHFFFAOYSA-N

Data  4 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 4 hits for monomerid = 523918   

TargetTyrosine-protein kinase JAK3(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523918(US11136329, Compound 18 | ethyl 2-(4-((7-(2- cyclo...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523918(US11136329, Compound 18 | ethyl 2-(4-((7-(2- cyclo...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523918(US11136329, Compound 18 | ethyl 2-(4-((7-(2- cyclo...)
Affinity DataIC50: 550nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523918(US11136329, Compound 18 | ethyl 2-(4-((7-(2- cyclo...)
Affinity DataIC50: 1.00E+4nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent